drug · protein
Wegovy
pre_registrationupdated 6mo agoby Novo Nordisk AS🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugOzempic222 co-mentions · 76 sources
- tagApproval176 co-mentions · 44 sources
- drugWegovy Pill168 co-mentions · 74 sources
- drugRybelsus121 co-mentions · 73 sources
- drugsemaglutide120 co-mentions · 72 sources
- tagSmall Molecule35 co-mentions · 18 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc23 co-mentions · 4 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
targets
Glucagon-like peptide 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying Wegovy
- phase3AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- phase1Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
- phase3A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- phase4Semaglutide vs Sitagliptin
- phase3A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase3A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
News(10)
- STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesityHow obesity medications may become the next big battleground over access to medicines in lower-income countries.stat · 10h ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 14h ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 3d ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 4d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 5d ago
- STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and moreThe FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…stat · 6d ago
- Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorderHaving linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.biospace · 6d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 7d ago
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 7d ago
- Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.biospace · 7d ago
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that